跳至主要内容
临床试验/CTRI/2022/06/043109
CTRI/2022/06/043109尚未招募未知

Assessment of prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design

ICMR Adhoc extramural grant0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Newly diagnosed triple-negative breast cancer.
  • Age 18 -65 years.
  • ECOG PS 0/1.
  • Early and locally advanced breast cancer (T2/T3/T4b with or without node positive).
  • Planned for neo-adjuvant chemotherapy with anthracycline and taxanes.
  • Bone marrow function- Hb > 9g%, absolute neutrophil count > 1500/ micL, platelet > 1.5 lakhs/ mic L.
  • Renal function- Serum creatinine < 1.5 mg%.
  • Liver function- Serum bilirubin > 1.5 mg%.
  • Normal cardiac function.Â

排除标准

  • The patient is not willing to the second biopsy
  • Pregnant women
  • Breast feeding mother
  • Prior history of any other malignancy
  • Bilateral breast cancer
  • Patient having active local site infection
  • Previous allergy to chemotherapy drugs paclitaxel and carboplatin

研究者

发起方
ICMR Adhoc extramural grant

相似试验